Skip to main content
. 2022 Aug 21;113(10):3618–3632. doi: 10.1111/cas.15521

FIGURE 7.

FIGURE 7

Reduced active β‐catenin production and membranous localization in GPC3‐Ab‐treated OSDX tissues. (A) Immunofluorescence and immunohistochemical (insets) illustration of active β‐catenin in OSDX tissues with and without (control) GPC3‐Ab treatment (×20). (B) Western blot analysis of the total and active β‐catenin levels in OSDX tissues with and without GPC3‐Ab treatment. GAPDH was used as a quantitative control for analysis (gray)